Muramyl dipeptide-based analogs as potential anticancer compounds: Strategies to improve selectivity, biocompatibility, and efficiency

Eliza Iwicka; Justyna Hajtuch; Krystyna Dzierzbicka; Iwona Inkielewicz-Stępniak

doi:10.3389/fonc.2022.970967

Muramyl dipeptide-based analogs as potential anticancer compounds: Strategies to improve selectivity, biocompatibility, and efficiency

Abstrakt

According to the WHO, cancer is the second leading cause of death in the world. This is an important global problem and a major challenge for researchers who have been trying to find an effective anticancer therapy. A large number of newly discovered compounds do not exert selective cytotoxic activity against tumorigenic cells and have too many side effects. Therefore, research on muramyl dipeptide (MDP) analogs has attracted interest due to the urgency for finding more efficient and safe treatments for oncological patients. MDP is a ligand of the cytosolic nucleotide-binding oligomerization domain 2 receptor (NOD2). This molecule is basic structural unit that is responsible for the immune activity of peptidoglycans and exhibits many features that are important for modern medicine. NOD2 is a component of the innate immune system and represents a promising target for enhancing the innate immune response as well as the immune response against cancer cells. For this reason, MDP and its analogs have been widely used for many years not only in the treatment of immunodeficiency diseases but also as adjuvants to support improved vaccine delivery, including for cancer treatment. Unfortunately, in most cases, both the MDP molecule and its synthesized analogs prove to be too pyrogenic and cause serious side effects during their use, which consequently exclude them from direct clinical application. Therefore, intensive research is underway to find analogs of the MDP molecule that will have better biocompatibility and greater effectiveness as anticancer agents and for adjuvant therapy. In this paper, we review the MDP analogs discovered in the last 10 years that show promise for antitumor therapy. The first part of the paper compiles the achievements in the field of anticancer vaccine adjuvant research, which is followed by a description of MDP analogs that exhibit promising anticancer and antiproliferative activity and their structural changes compared to the original MDP molecule.

Cytowania

1 3

CrossRef
0

Web of Science
8

Scopus

Autorzy (4)

Eliza Iwicka
- GUMed
Justyna Hajtuch mgr
- GUMed
Krystyna Dzierzbicka prof. dr hab. inż.
Iwona Inkielewicz-Stępniak
- GUMed

Cytuj jako

Pełna treść

pobierz publikację

pobrano 55 razy

Wersja publikacji: Accepted albo Published Version
DOI:: Cyfrowy identyfikator dokumentu elektronicznego (otwiera się w nowej karcie) 10.3389/fonc.2022.970967
Licencja: otwiera się w nowej karcie

pełna treść artykułu zobacz w serwisie zewnętrznym otwiera się w nowej karcie

Słowa kluczowe

MURAMYL DIPEPTIDE, MURAMYL DIPEPTIDE ANALOGS, ANTICANCER COMPOUNDS, ANTICANCER ACTIVITY, NOD2 RECEPTOR, ADJUVANT THERAPY

Informacje szczegółowe

Kategoria:

Publikacja w czasopiśmie

Typ:

artykuły w czasopismach

Opublikowano w:

Frontiers in Oncology nr 12,
ISSN: 2234-943X

Język:

angielski

Rok wydania:

2022

Opis bibliograficzny:

Iwicka E., Hajtuch J., Dzierzbicka K., Inkielewicz-Stępniak I.: Muramyl dipeptide-based analogs as potential anticancer compounds: Strategies to improve selectivity, biocompatibility, and efficiency// Frontiers in Oncology -Vol. 12, (2022), s.970967-

DOI: